Aardvark Therapeutics, Inc.
AARD
$8.49
-$0.50-5.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 32.24% | 181.64% | 99.43% | 35.89% | 175.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 160.96% | 382.27% | 323.20% | 196.16% | 250.74% |
| Operating Income | -160.96% | -382.27% | -323.20% | -196.16% | -250.74% |
| Income Before Tax | -163.66% | -327.46% | -330.13% | -98.29% | -256.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -163.66% | -327.46% | -330.13% | -98.29% | -256.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -163.66% | -327.46% | -330.13% | -98.29% | -256.38% |
| EBIT | -160.96% | -382.27% | -323.20% | -196.16% | -250.74% |
| EBITDA | -160.86% | -382.48% | -- | -- | -- |
| EPS Basic | 51.76% | -28.52% | -319.80% | -97.09% | -255.48% |
| Normalized Basic EPS | 52.05% | -35.14% | -302.94% | -156.73% | -376.53% |
| EPS Diluted | 51.76% | -28.52% | -319.80% | -97.09% | -255.48% |
| Normalized Diluted EPS | 52.05% | -35.14% | -302.94% | -156.73% | -376.53% |
| Average Basic Shares Outstanding | 446.63% | 232.59% | 2.46% | 0.61% | 0.26% |
| Average Diluted Shares Outstanding | 446.63% | 232.59% | 2.46% | 0.61% | 0.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |